Lifecore Biomedical, Inc. · NASDAQ:LFCR
Lifecore Biomedical — Merger or Acquisition (September 2026)
11 slides from Lifecore Biomedical's merger presentation, Sep 28, 2026
Slide 1: An Exciting Path Forward
An Exciting Path Forward September 28, 2026 EXHIBIT 99.3
Slide 2: Caution Regarding Forward-Looking Statements
Caution Regarding Forward-Looking Statements This presentation relates to the proposed transaction pursuant to which Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) will be acquired by Lifecore Inc., a Delaware corporation (“Parent”). Pursuant to an Agreement and Plan of Merger dated Septemb
Slide 3: Additional Information and Where to Find It; Participants in the Solicitation
Additional Information and Where to Find It; Participants in the Solicitation Additional Information and Where to Find It In connection with the proposed acquisition of Lifecore by an affiliate of Webster Equity Partners, Lifecore will file with the SEC a definitive proxy statement relating to a Lif
Slide 4: Acquisition Announcement
Acquisition Announcement Lifecore has entered into a definitive merger agreement to be acquired by an affiliate of Webster Equity Partners. At closing, Lifecore will become privately held. Transaction Highlights: $6.28 per share of common stock in cash at closing plus one CVR per share of common sto
Slide 5: The Lifecore Board's Process
The Lifecore Board’s Process Unanimously Approved: The Lifecore Transaction Committee and Lifecore Board of Directors unanimously approved the merger. Attractiveness of Lifecore Opportunity To Buyer Benefits and Risks of Standalone Plan Best Interest of Stockholders
Slide 6: What This Transaction Means for Our Employee Community
What This Transaction Means for Our Employee Community No organizational changes between now and closing, except backfill of certain open and approved positions 2026 Annual Bonus Plan continues to be in effect Lifecore will provide base salary, short-term cash incentive compensation, severance pay a
Slide 7: Buyer Profile
Buyer Profile Healthcare-industry-focused private equity. Pharma and CDMO experience. We believe buyer supports our growth plans.
Slide 8: Continuity is Key
Continuity is Key Transaction represents ownership change. Does not change our business priorities. Meet our customer commitments with no change in daily activities. Customers and key suppliers will receive communication about continuity. Focus on strong finish to 2026. Post-close, we expect Lifecor
Slide 9: What Happens Next?
What Happens Next? Proposed acquisition publicly announced via press release today. “Go-shop” period begins immediately. Transaction is subject to a number of closing conditions: Expect to close at the end of Q4 2026 Approval by Lifecore’s stockholders Receipt of required regulatory approval Please
Slide 10: Alcon Contract Manufacturing Agreement Extension
Alcon Contract ManufacturingAgreement Extension Growth by maximizing existing commercial business
Slide 11: Thank you
Thank you EXHIBIT 99.4 Lifecore Biomedical, Inc. Transcript of CEO Remarks Accompanying Employee Presentation September 28, 2026 Slide 1 Good morning, everyone, and thank you for joining me today. As you know, we’re here to talk about the exciting announcement we made this morning about Lifecore’s n
Lifecore Biomedical, Inc. \de\ — Merger or Acquisition (September 2026) on 6ix